Tvax Biomedical Inc. , Lenexa, Kan. Business: Cancer, Infectious Date completed: 1/7/13 Type: Venture financing Raised: $2 million Investors: Not disclosed Note: Tvax raised $2 million in the first close of a planned $10 million financing...

Tvax Biomedical Inc. , Lenexa, Kan. Business: Cancer, Infectious Hired: Philip Haworth as CEO, formerly CEO of Silence Therapeutics plc ; he succeeds Gary Wood, who becomes CSO WIR Staff cancer Infectious...

Tvax Biomedical Inc. , Lenexa, Kan. Business: Cancer, Infectious Date announced: 5/17/12 Type: IPO Underwriters: Roth Capital Partners; Cantor Fitzgerald; Aegis Capital Note: Tvax withdrew its IPO, citing market conditions. WIR Staff cancer Infectious...

Tvax Biomedical Inc. , Lenexa, Kan. Business: Cancer, Infectious Date announced: 1/23/12 Type: IPO To be raised: Up to $25.3 million Shares: 2 million Price: $9-$11 Underwriters: Roth Capital Partners; Cantor Fitzgerald; Aegis Capital Overallotment: 300,000...

Tvax Biomedical Inc. , Lenexa, Kan. Business: Cancer, Infectious Date announced: 11/7/11 Type: IPO To be raised: Up to $40 million Shares: TBD Price: TBD Underwriters: Roth Capital Partners; Cantor Fitzgerald; Morgan Joseph TriArtisan WIR Staff...